Drug Delivery to the Ischemic Brain
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Cerebral ischemia occurs when blood flow to the brain is insufficient to meet metabolic demand. This can result from cerebral artery occlusion that interrupts blood flow, limits CNS supply of oxygen and glucose, and causes an infarction/ischemic stroke. Ischemia initiates a cascade of molecular events inneurons and cerebrovascular endothelial cells including energy depletion, dissipation of ion gradients, calcium overload, excitotoxicity, oxidative stress, and accumulation of ions and fluid. Blood-brain barrier (BBB) disruption is associated with cerebral ischemia and leads to vasogenic edema, a primary cause of stroke-associated mortality. To date, only a single drug has received US Food and Drug Administration (FDA) approval for acute ischemic stroke treatment, recombinant tissue plasminogen activator (rt-PA). While rt-PA therapy restores perfusion to ischemic brain, considerable tissue damage occurs when cerebral blood flow is re-established. Therefore, there is a critical need for novel therapeutic approaches that can “rescue” salvageable brain tissue and/or protect BBB integrity during ischemic stroke. One class of drugs that may enable neural cell rescue following cerebral ischemia/reperfusion injury is the HMG-CoA reductase inhibitors (i.e., statins). Understanding potential CNS drug delivery pathways for statins is critical to their utility in ischemic stroke. Here, we review molecular pathways associated with cerebral ischemia and novel approaches for delivering drugs to treat ischemic disease. Specifically, we discuss utility of endogenous BBB drug uptake transporters such as organic anion transporting polypeptides (OATPs/Oatps) and nanotechnology-based carriers for optimization of CNS drug delivery. Overall, this chapter highlights state-of-the-art technologies that may improve pharmacotherapy of cerebral ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial formation of reactive oxygen species
Turrens, J. F. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2003.049478 · Cited by 5,084
Thresholds in cerebral ischemia - the ischemic penumbra.
Astrup, J., Siesjö, B. K., & Symon, L. (1981) · Stroke · doi:10.1161/01.str.12.6.723 · Cited by 2,820
Biodegradable nanoparticles for drug delivery and targeting
Hans, M. L., & Lowman, A. M. (2002) · Current Opinion in Solid State and Materials Science · doi:10.1016/s1359-0286(02)00117-1 · Cited by 1,324 · cited 4×
“The chemical nature of PEG allows liposomes to circulate in the bloodstream longer, avoiding collection by the RES in the liver and spleen (Hans & Lowman, 2002; Pinzon-Daza et al., 2013; Xie et al., 2012).”
BackgroundInfluentialNanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107 · cited 1×
“Apolipoprotein E (ApoE), found in blood plasma, has been shown to adsorb on the surface of the polysorbate 20-, 40-, 60-, or 80-coated nanoparticles and likely mimics LDL, allowing receptor binding (Kreuter, 2001).”
BackgroundGuzy, R. D., & Schumacker, P. T. (2006) · Experimental Physiology · doi:10.1113/expphysiol.2006.033506 · Cited by 881 · cited 1×
“This paradoxical increase of superoxide despite low oxygen concentrations has been well described (Guzy & Schumacker, 2006; Murphy, 2009).”
BackgroundThe Mechanism of Uptake of Biodegradable Microparticles in Caco-2 Cells Is Size Dependent
Desai, M. P., Labhasetwar, V., Walter, E., Levy, R. J., & Amidon, G. L. (1997) · Pharmaceutical Research · doi:10.1023/a:1012126301290 · Cited by 858
Association of Nitrotyrosine Levels With Cardiovascular Disease and Modulation by Statin Therapy
Shishehbor, M. H., Aviles, R. J., Brennan, M.-L., Fu, X., Goormastic, M., Pearce, G. L., Gokce, N., Keaney, J. F., Penn, M. S., Sprecher, D. L., et al. (2003) · JAMA · doi:10.1001/jama.289.13.1675 · Cited by 464 · cited 1×
“In addition to these preclinical studies, statin treatment has been shown to reduce cerebral expression of oxidative stress markers (i.e., nitrotyrosine and F2-isoprostanes) in clinical investigations (Davignon, Jacob, & Mason, 2004; Shishehbor et al., 2003).”
BackgroundSchreibelt, G., Kooij, G., Reijerkerk, A., van Doorn, R., Gringhuis, S. I., van der Pol, S., Weksler, B. B., Romero, I. A., Couraud, P., Piontek, J., et al. (2007) · The FASEB Journal · doi:10.1096/fj.07-8329com · Cited by 347 · cited 1×
“Production of ROS and subsequent oxidative stress alters expression and molecular organization of critical tight junction proteins claudin-5 and occludin at the BBB, leading to increased paracellular solute leak (Lochhead et al., 2010; Schreibelt et al., 2007).”
BackgroundMitochondrial reactive oxygen species and Ca 2+ signaling
Camello-Almaraz, C., Gomez-Pinilla, P. J., Pozo, M. J., & Camello, P. J. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00217.2006 · Cited by 336
Lochhead, J. J., McCaffrey, G., Quigley, C. E., Finch, J., DeMarco, K. M., Nametz, N., & Davis, T. P. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.29 · Cited by 334 · cited 4×
“Specifically, TEMPOL prevents breakage of disulfide bonds on occludin thereby blocking disruption of occludin oligomeric assemblies and subsequent blood-to-brain leak of circulating solutes (Lochhead et al., 2010).”
BackgroundInfluentialThe CNS microvascular pericyte: pericyte-astrocyte crosstalk in the regulation of tissue survival
Bonkowski, D., Katyshev, V., Balabanov, R. D., Borisov, A., & Dore-Duffy, P. (2011) · Fluids and Barriers of the CNS · doi:10.1186/2045-8118-8-8 · Cited by 207
Nanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Ose, A., Kusuhara, H., Endo, C., Tohyama, K., Miyajima, M., Kitamura, S., & Sugiyama, Y. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029454 · Cited by 148 · cited 4×
“For example, DPDPE is a P-gp substrate as well as an Oatp1a4 substrate (Ose et al., 2010; Ronaldson et al., 2011).”
BackgroundInfluentialO'Donnell, M. E., Lam, T. I., Tran, L. Q., Foroutan, S., & Anderson, S. E. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600278 · Cited by 107
Rak, R., Chao, D. L., Pluta, R. M., Mitchell, J. B., Oldfield, E. H., & Watson, J. C. (2000) · Journal of Neurosurgery · doi:10.3171/jns.2000.92.4.0646 · Cited by 106 · cited 1×
“…(TEMPOL) treatment, a superoxide scavenging antioxidant that readily crosses the BBB (Cuzzocrea et al., 2000; Deng-Bryant, Singh, Carrico, & Hall, 2008; Kwon et al., 2003; Lochhead et al., 2012; Rak et al., 2000; Saito, Takeshita, Ueda, & Ozawa, 2003; Zhelev et al., 2009).”
BackgroundLocalization of the Na + -d-glucose cotransporter SGLT1 in the blood-brain barrier
Elfeber, K., K�hler, A., Lutzenburg, M., Osswald, C., Galla, H.-J., Witte, O. W., & Koepsell, H. (2004) · Histochemistry and Cell Biology · doi:10.1007/s00418-004-0633-9 · Cited by 82
Barone, E., Mancuso, C., Di Domenico, F., Sultana, R., Murphy, M. P., Head, E., & Butterfield, D. A. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07538.x · Cited by 75 · cited 2×
“Of particular note, Barone et al. (2012) reported that increased activity of biliverdin reductase-A induced by atorvastatin was inversely correlated with indices of oxidative stress, which points towards an antioxidant mechanism for statins.”
BackgroundThompson, B. J., Sanchez-Covarrubias, L., Slosky, L. M., Zhang, Y., Laracuente, M.-L., & Ronaldson, P. T. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.4 · Cited by 72 · cited 17×
“The ratio of cleaved-to-uncleaved PARP is an established early indicator of end-stage cell death (Chaitanya et al., 2010; Thompson et al., 2014).”
BackgroundMethodInfluentialSelf-citationSynergistic Effect of Cold Mannitol and Na+/Ca2+ Exchange Blocker on Blood–Brain Barrier Opening
Ikeda, M., Bhattacharjee, A. K., Kondoh, T., Nagashima, T., & Tamaki, N. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2002.6495 · Cited by 62
Westholm, D. E., Stenehjem, D. D., Rumbley, J. N., Drewes, L. R., & Anderson, G. W. (2009) · Endocrinology · doi:10.1210/en.2008-0188 · Cited by 53
Cited by
Surface functionalized exosomes as targeted drug delivery vehicles for cerebral ischemia therapy
Tian, T., Zhang, H.-X., He, C.-P., Fan, S., Zhu, Y.-L., Qi, C., Huang, N.-P., Xiao, Z.-D., Lu, Z.-H., Tannous, B. A., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.012 · Cited by 1,154
Abdullahi, W., Tripathi, D., & Ronaldson, P. T. (2018) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00095.2018 · Cited by 613
Self-citationGlucose transporters in brain in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02441-x · Cited by 558
“The arterial occlusion causes irreversible structural damages in a core region and changes in a surrounding area called penumbra that may be reversible [17, 237, 398].”
BackgroundIschemia-Triggered Glutamate Excitotoxicity From the Perspective of Glial Cells
Belov Kirdajova, D., Kriska, J., Tureckova, J., & Anderova, M. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00051 · Cited by 428
Ronaldson, P. T., & Davis, T. P. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20951995 · Cited by 392
Self-citation
Metadata
- Authors
- Thompson, B. J., & Ronaldson, P. T.
- Venue
- Advances in Pharmacology
- Publisher
- Elsevier
- Published
- 2014
- Volume
- 71
- Pages
- 165-202
- ISSN
- 1054-3589 (ISSN-L)
- OpenAlex
- W2404708375
- Cited by
- 107
- References
- 20
- FWCI
- 23.81
- Type
- book chapter
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.